Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

(MENAFN- EIN Presswire) Duchenne ... clinical decision-making, including genetic counseling, prenatal diagnosis, and consideration of mutation-specific therapies. The Duchenne Muscular Dystrophy ...

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...

An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...

UC Davis Health has premiered a new documentary on a family’s urgent journey across the globe to get their toddler in a clinical trial for patients with Duchenne Muscular Dystrophy, or DMD.

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the ...

FSHD is the second most common form of muscular dystrophy after the Duchenne type ... drug candidate to take forward into preclinical and clinical testing has been selected.

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (Vamorolone) in countries where the product ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle ... 2008). Despite their distinct clinical features, FSHD and BMD exhibit a wide range of overlapping phenotypic spectrum, ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...